Skip to content
Three questions men can ask about prostate cancer
Prostate cancer is the most common solid cancer among men, with 1 in 8 men being diagnosed in their lifetime and 1 in 44 […]
Three questions men can ask about prostate cancer Read More »
Latest News
BIO visit shines a spotlight on Virginia’s biotech ecosystem
With more than $1 billion in R&D expenditures in 2022 and 415 new patents in 2023, the bioscience sector in Virginia is making an
BIO visit shines a spotlight on Virginia’s biotech ecosystem Read More »
Life sciences job report shows growth slowing, but firms still invest in talent
As the United States has long been a life sciences leader, the health of the life sciences sector is a pretty good indicator of
Life sciences job report shows growth slowing, but firms still invest in talent Read More »
Protect IP protections, BIO 2025 panel urges
Given the essential role that intellectual property plays in the development of lifesaving scientific advances, we need to defend and strengthen policy that protects
Protect IP protections, BIO 2025 panel urges Read More »
BIO 2025: The urgent need to address AMR and cancer
As antimicrobial resistance (AMR) continues to threaten global public health, its impact on cancer patients is a growing, often overlooked crisis. Patients with cancer
BIO 2025: The urgent need to address AMR and cancer Read More »
BIO expert explains patents at DOJ and FTC listening session
Patents enable the innovation that produces new lifesaving treatments while ensuring a competitive market, the top IP expert for the Biotechnology Innovation Organization (BIO)
BIO expert explains patents at DOJ and FTC listening session Read More »
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the
A conversation with Fritz Bittenbender, new BIO Board Chair Read More »
Onerous reporting requirements crushing small biotechs, BIO Board member testifies
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements that cost $1 million or more, cutting into the firms’ ability
Onerous reporting requirements crushing small biotechs, BIO Board member testifies Read More »
BIO 2025: The innovation race vs. the regulatory pace
We often talk about the exciting jumps in technology and innovation that improve and save lives. What is less frequently discussed is how regulation
BIO 2025: The innovation race vs. the regulatory pace Read More »
BIO 2025: The world can’t wait – it needs to collaborate
Biotech is a global business, and we’re better for it, said experts at the 2025 Biotechnology Innovation Organization (BIO) International Convention in Boston. International
BIO 2025: The world can’t wait – it needs to collaborate Read More »